Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 11;15(18):4512.
doi: 10.3390/cancers15184512.

The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy

Erkan Topkan  1 , Ugur Selek  2 , Berrin Pehlivan  3 , Ahmet Kucuk  4 , Duriye Ozturk  5 , Beyza Sirin Ozdemir  6 , Ali Ayberk Besen  7 , Huseyin Mertsoylu  8
Affiliations

The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy

Erkan Topkan et al. Cancers (Basel). .

Abstract

Background: We sought to determine the prognostic value of the newly developed Global Immune-Nutrition-Inflammation Index (GINI) in patients with stage IIIC non-small cell lung cancer (NSCLC) who underwent definitive concurrent chemoradiotherapy (CCRT).

Methods: This study was conducted on a cohort of 802 newly diagnosed stage IIIC NSCLC patients who underwent CCRT. The novel GINI created first here was defined as follows: GINI = [C-reactive protein × Platelets × Monocytes × Neutrophils] ÷ [Albumin × Lymphocytes]. The receiver operating characteristic (ROC) curve analysis was used to determine the optimal pre-CCRT GINI cut-off value that substantially interacts with the locoregional progression-free (LRPFS), progression-free (PFS), and overall survival (OS).

Results: The optimal pre-CCRT GINI cutoff was 1562 (AUC: 76.1%; sensitivity: 72.4%; specificity: 68.2%; Youden index: 0.406). Patients presenting with a GINI ≥ 1562 had substantially shorter median LRPFS (13.3 vs. 18.4 months; p < 0.001), PFS (10.2 vs. 14.3 months; p < 0.001), and OS (19.1 vs. 37.8 months; p < 0.001) durations than those with a GINI < 1562. Results of the multivariate analysis revealed that the pre-CCRT GINI ≥ 1562 (vs. <1562), T4 tumor (vs. T3), and receiving only 1 cycle of concurrent chemotherapy (vs. 2-3 cycles) were the factors independently associated with poorer LRPS (p < 0.05 for each), PFS (p < 0.05 for each), and OS (p < 0.05 for each).

Conclusion: The newly developed GINI index efficiently divided the stage IIIC NSCLSC patients into two subgroups with substantially different median and long-term survival outcomes.

Keywords: Global Immune-Nutrition-Inflammation Index; biological marker; chemoradiotherapy; non-small cell lung cancer; prognosis; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Receiver operating characteristic curve analysis results depicting the association between the pretreatment Global Immune-Nutrition-Inflammation Index values and survival outcomes: (A) Locoregional progression-free survival, (B) Progression-free survival, and (C) Overall survival.
Figure 2
Figure 2
Survival outcomes per Global Immune-Nutrition-Inflammation Index (GINI) groups (Dark blue: GINI < 1562; Red: GINI ≥ 1562): (A) Locoregional progression-free survival, (B) Progression-free survival, and (C) Overall survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Antonia S.J., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Yokoi T., Chiappori A., Lee K.H., De Wit M., et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2017;377:1919–1929. doi: 10.1056/NEJMoa1709937. - DOI - PubMed
    1. Gray J.E., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Kurata T., Chiappori A., Lee K.H., Cho B.C., et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC. J. Thorac. Oncol. 2020;15:288–293. doi: 10.1016/j.jtho.2019.10.002. - DOI - PMC - PubMed
    1. Topkan E., Ozdemir Y., Kucuk A., Besen A.A., Mertsoylu H., Sezer A., Selek U. Significance of overall concurrent chemora-diotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients. PLoS ONE. 2019;14:e0218627. - PMC - PubMed
    1. Topkan E., Selek U., Kucuk A., Haksoyler V., Ozdemir Y., Sezen D., Mertsoylu H., Besen A.A., Bolukbasi Y., Ozyilkan O., et al. Prechemoradiotherapy Systemic inflammation response index stratifies stage iiib/c non-small-cell lung cancer pa-tients into three prognostic groups: A propensity score-matching analysis. J. Oncol. 2021;2021:6688138. doi: 10.1155/2021/6688138. - DOI - PMC - PubMed
    1. Oberije C., De Ruysscher D., Houben R., van de Heuvel M., Uyterlinde W., Deasy J.O., Belderbos J., Dingemans A.-M.C., Rimner A., Din S., et al. A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients. Int. J. Radiat. Oncol. 2015;92:935–944. doi: 10.1016/j.ijrobp.2015.02.048. - DOI - PMC - PubMed